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This article contains raw and processed data related to research pub-
lished in “Role of the polypeptide N-acetylgalactosaminyltransferase 3 in
ovarian cancer progression: possible implications in abnormal mucin O-
glycosylation” [1]. The data presented here was obtained with the
application of a bioorthogonal chemical reporter strategy analyzing
differential glycoprotein expression following the knock-down (KD) of
the GALNT3 gene in the epithelial ovarian cancer (EOC) cell line
A2780s. LC-MS/MS mass spectrometry analysis was then performed
and the processed data related to the identiﬁed glycoproteins show
that several hundred proteins are differentially expressed between
control and GALNT3 KD A2780s cells. The obtained data also uncover
numerous novel glycoproteins; some of which could represent new
potential EOC biomarkers and/or therapeutic targets.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
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e generation of the presented data.
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ject areaOncology, Proteomicsype of data Table, ﬁgure
ow data was
acquiredMass spectrometry, Orbitrap Fusion mass spectrometer (Thermo Fisher Sci-
entiﬁc, San Jose, CA, USA)ata format Raw, analyzed
xperimental
factorsMetabolite labeling of glycoproteins from extracellular/membrane bound,
cytoplasmic and nuclear fractions of ovarian cancer cells, followed by trypsin
digestion and glycoproteomics enrichment using Click Chemistry, and sub-
jected to nanoLC and analyzed by ESI MS/MS.xperimental
featuresSubcellular fractionation, ESI MS/MS peptide identiﬁcation, data analysis in
MaxQuant followed by data predictions using the NetOGlyc 4.0 and NetNGlyc
1.0 servers, and enrichment analysis using GO Consortium for enrichment
analysis.ata source
locationQuebec City, Canadaata accessibility Data is with this articleValue of the data The presented list of differentially regulated glycoproteins identiﬁed upon GALNT3 KD in EOC cells
could represent novel putative biomarkers/molecular targets involved in EOC metastasis and thus
the data presented here can be a useful resource to examine some of these biomarkers.
 The metabolic labeling approach applied in this study followed by the MS analysis could be a useful
tool/guide for the quantiﬁcation and the identiﬁcation of glycoproteins from different cell lines.
 The data presented herein provide a comprehensive list of newly identiﬁed glycoproteins, which
strongly suggests that the metabolic labeling approach applied can essentially increase the mag-
nitude of recognized glycoproteins by comparing to organism-speciﬁc database for a more
complete level of identiﬁcation.1. Data
The datasets provided in this article represent the entire list of identiﬁed glycoproteins after
GalNAz metabolic labeling in both control and GALNT3 KD A2780s cells, in addition to the processed
data identifying the quantitatively signiﬁcant list of differentially regulated proteins between the
control and GALNT3 KD cells. Data represented here also include comparative analysis of identiﬁed
glycoproteins with previously published glycoproteins’ data. This was also supported by predictive
analysis performed by investigating for possible glycosylation sites from the list of the identiﬁed
proteins for further conﬁrmation. Finally, data of protein enrichment analysis performed were
included as a representation of the cellular localization of the assigned glycoproteins from our list of
differentially regulated proteins.2. Experimental design, materials and methods
We applied a bioorthogonal chemical reporter strategy [2,3] for analyzing differential glycoprotein
expression following GALNT3 KD in the EOC cell line A2780s. Fig. 1 represents a schematic overview of the
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Fig. 2. Western blot analysis of glycoproteins enrichment in control and GALNT3 KD A2780s cells. Whole-cell lysates labeled
with 100 μM Ac4GalNAz were incubated with a biotinylated bioorthogonal probe. Anti-biotin signal was checked before afﬁ-
nity-capture (Load) and after afﬁnity-capture on the fraction not bound to the beads (Supernatant) and on the fraction that
included the bead after washing (Capture).
Fig. 1. Schematic overview of the glycoproteomic workﬂow used.
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R. Sheta et al. / Data in Brief 8 (2016) 342–349 345glycoproteomic workﬂow used. The method is explicitly used for metabolically labeling glycans with a
monosaccharide precursor attached to a functional azido group [4]. Control and GALNT3 KD A2780s cells
were separately labeled with tetraacetylated N-azidoacetylgalactosamine (Ac4GalNAz) or tetraacetylated N-
acetylgalactosamine (Ac4GalNAc, negative control). The labeled control and GALNT3 KD A2780s cells were
then subjected to subcellular fractionation (conditioned media fraction, soluble fraction and insoluble frac-
tion) followed by glycoprotein enrichment (Fig. 1). A Western blot analysis was performed to examine the
enrichment efﬁciency (Fig. 2). Trypsin digestion was then performed and the released peptides were ana-
lyzed by LC–MS/MS. For each sample labeled with Ac4GalNaz, three technical replicates were performed in
order to get statistical values on intensity measurements, while single injections of Ac4GalNAc samples were
done for evaluation of non-speciﬁc binding on streptavidin-agarose resin.
Supplementary Table 1 displays the total number of proteins identiﬁed in the three subcellular frac-
tions of the control and GALNT3 KD A2780s cells cultured with Ac4GalNAz, as well as the subtracted
proteins, exclusively found in the Ac4GalNAc (negative control) fraction. Analyses of these data using the
NetOGlyc 4.0 and the NetNGlyc 1.0 servers generated lists of proteins with predicted O- and N-
glycosylation sites (see Supplementary Table 2). Additionally, Supplementary Table 3 contains a list of
proteins identiﬁed in our study that have been previously characterized as glycoproteins in the literature.
The MaxQuant software and Andromeda search engine (included in MaxQuant) [5,6] were con-
secutively used to generate a list of differentially regulated proteins identiﬁed in the three A2780s
subcellular fractions upon GALNT3 KD, as based on the following criteria: Welch test p-value r0.05 and
fold change in relative expression of Z2 similar to that applied in [7,,8] (see Supplementary Table 4).
Cellular component Gene Ontology (GO) analysis of the differentially regulated glycoproteins identiﬁed
between the control and GALNT3 KD A2780s cells was additionally performed on each of the identiﬁed
fractions (conditioned media fraction, cytosolic fraction and nuclear fraction), and data were compared
to the entire human proteome using the GO Consortium for enrichment analysis (Fig. 3).Fig. 3. GO cellular component analysis of signiﬁcantly enriched proteins found upon GALNT3 KD. Bar graphs showing the cellular
component GO terms that are signiﬁcantly enriched from the differentially regulated proteins in our study, compared to the entire
human proteome. Data were submitted to the GO Consortium for enrichment analysis [20]. The analysis was performed on the
differentially regulated proteins identiﬁed from each of the three fractions: Conditioned media fraction (blue bars), Soluble fraction
(red bars) and Insoluble fraction (green bars). All identiﬁed proteins annotated with GO cellular component terms were compared
against the annotated human proteome. The enrichment p-value (r0.05) of each term was transformed to a –log10 (p-value).
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The ﬁrst part of the platform protocol applied in this study represents a method used to meta-
bolically label glycoproteins in cell culture, as described in [1]. Brieﬂy, cells were separately labeled
with Ac4GalNAz and Ac4GalNAc (Fig. 1). We started by isolating and enriching glycoproteins from
different biological fractions, including proteins secreted into the media (conditioned media fraction),
as well as proteins enriched in the cytosolic and nuclear and fractions (soluble and insoluble fractions
respectively), as shown in [1].
The next step of the protocol was the chemical glycoproteomics enrichment procedure, which
included tagging glycoproteins with Click Chemistry (Fig. 1). The Copper-Catalyzed Azide-Alkyne
Cycloaddition (CuAAC) enrichment was performed, as previously described [9,10]. GalNAz and GalNAc
labeled cell fractions were divided into aliquots, each containing 3 mg of protein. Click-chemistry
reagents (200 mM alkynyl biotin probe, 300 mM copper sulfate, 600 mM BTTP, and 2.5 mM sodium
ascorbate) were pre-mixed and added, and the reaction was incubated for 3.5 h at 24 °C. Proteins were
precipitated, resuspended and then solubilized as previously described [9,10]. Brieﬂy, protein pellets
were resuspended in 400 μl 1% RapiGest/PBS and solubilized by probe sonication. Streptavidin-agarose
resin was ﬁrst washed with PBS and then added to the samples, and the resulting mixture was incu-
bated for 12 h at 24 °C with rotation. The beads were then pelleted by centrifugation, and the super-
natant containing uncaptured proteins was removed as a separate fraction (Fig. 1). The beads were then
washed with 1% Rapigest, 6 M urea and PBS; beads were then pelleted by centrifugation and resus-
pended in PBS. Samples were subjected to reduction and alkylation, as previously described [9,10].
Brieﬂy, proteins were reduced by the addition of 5 mM DTT followed by alkylation completed by the
addition of 10 mM iodoacetamide. Trypsin was then added to the slurry of beads and the resulting
mixture was incubated for 12 h at 37 °C. The beads were pelleted and the supernatant digest was
collected (Fig. 1). The trypsin fraction was concentrated to dryness using a Speedvac set to 40 °C.
Samples were desalted by ZipTip P10 for subsequent MS analysis (Fig. 1).4. Western blot analysis
Western blot analyses were performed on protein lysates collected from both the control and
GALNT3 KDA2780s EOC cells. Whole-cell lysates labeled with 100 μMAc4GalNAz were incubated with a
biotinylated bioorthogonal probe. Biotinylated glycoproteins were enriched from the supernatant by
afﬁnity-capture with streptavidin–agarose beads. To each aliquot collected during the enrichment
procedure, 3 μl of 4X SDS buffer was added and the aliquots were loaded to 5% polyacrylamide gels.
Proteins were then transferred to nitrocellulose membranes, which were consecutively incubated with
Ponceau stain (Fig. 2). The membranes were then blocked with 2% bovine serum albumin in Tris-
buffered saline with 0.1% Tween-20 for 1 h at 24 °C with gentle shaking and washed 3 with PBS-
Tween. The blots were stained with streptavidin–HRP (1:1000) (Pierce, Streptavidin Poly-HRP) over-
night at 4 °C with gentle shaking. Upon washing with PBS-Tween, the membranes were developed
using the ECL Chemiluminescent Substrate (OriGene). Fig. 2 shows a Western blot demonstrating the
incorporation of GalNAz into glycoproteins from protein lysates collected from the three fractions
(conditioned media fraction, soluble and insoluble fractions). Anti-biotin signal was checked before
afﬁnity-capture (Load) and after afﬁnity-capture on the fraction not bound to the beads (Supernatant)
and on the fraction that included the bead after washing (Capture), as performed in [9] (Fig. 2).5. Database searching and label free quantiﬁcation
The released glycopeptides were consecutively analyzed by reversed-phase nanoﬂow liquid chro-
matography coupled to a Thermo LTQ–Orbitrap fusion mass spectrometer, as described in [1] (also see
Fig. 1). Spectra were searched against a human proteins database (Uniprot Complete Proteome – tax-
onomy Homo sapiens – 69165 sequences) using the Andromeda module of MaxQuant software v.
1.5.2.8 [6,11]. Trypsin/P enzyme parameter was selected with two possible missed cleavages.
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ylation of protein N-terminus were set as variable modiﬁcations, similar to that applied in [12]. Search
mass tolerances were deﬁned at 5 ppm and 0.6 Da for MS and MS/MS respectively. For protein vali-
dation, a maximum false discovery rate of 1% at peptide and protein level was used based on a target/
decoy search. MaxQuant was also applied for Label Free Quantiﬁcation (LFQ), as shown in [13]. The
‘match between runs’ optionwas used with a 20 min value as the alignment time window and 3 min as
match time window. Only unique and razor peptides were used for quantiﬁcation. The LFQ intensity
values (normalized values) extracted by MaxQuant for each protein in each sample replicate were used
to calculate a ratio between two samples to compare as well as a p-value based on aWelch's test similar
to that applied in [14] (see Supplementary Table 1). When LFQ intensity values were missing, they were
replaced either by the average of the values of the two other replicates, or, if less than two replicate
values were present, by a noise value corresponding to the ﬁrst percentile of LFQ values of all proteins
of the sample replicate, as described in [14] (see Supplementary Table 1). A protein was considered as
quantiﬁable only if at least two of the replicate values in one of the two samples to compare were
present before performing the missing values replacement (Supplementary Table 1).
Differentially regulated proteins between GALNT3 KD and control A2780s cells were deﬁned based
on the following selection criteria: 2-fold change in expression level and t-test p-value cutoff of
r0.05, as described [15–18]. A z-score was also calculated for each protein based on the statistical
approach described in [16], where z-score¼{(Welch t-test difference)Median (Welch t-test differ-
ence) for all quantiﬁed proteins}/Standard deviation (Welch t-test difference) for all quantiﬁed pro-
teins as described in [16].
To classify proteins as variant, different combinations of stringent ﬁltering criteria were tested
(Supplementary Table 4):
1. Filtering 1 (Welch p-value r0.05 and fold change of Z2)
2. Filtering 2 (Welch p-value r0.05 and z-score 41)
The list of the differentially regulated proteins is presented in Supplementary Table 4.6. Bioinformatic annotation & analysis
6.1. Glycoprotein prediction analysis
The NetOGlyc 4.0 server (http://www.cbs.dtu.dk/services/NetOGlyc-4.0/) was used to identify the
O-glycosylated proteins identiﬁed from our control and GALNT3 KD A2780s EOC cells, (using G-score
40.5), as described in [5]. The identiﬁed predicted O-glycosylated proteins are listed in Supple-
mentary Table 2.
The NetNGlyc 1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc/) was used to ﬁnd the N-
glycosylated proteins identiﬁed from our control and GALNT3 KD A2780s EOC cells. Sequences having
N-glycosylation potential 40.5 were considered as cut-off value [19]. The identiﬁed predicted N-
glycosylated proteins are listed in Supplementary Table 2.
An additional prediction approach used in our study was essentially focused on reviewing recent
literature for previously identiﬁed glycoproteins. The list of proteins identiﬁed and compared to the
literature data is found in Supplementary Table 3.
6.2. Protein enrichment analysis
GO enrichment analysis of the cellular localization of the identiﬁed differentially regulated pro-
teins was performed using information from AmiGO (http://amigo.geneontology.org). The GO term
enrichment tool was used to determine the observed level of annotations for the set of proteins from
our study and determine the signiﬁcance in the context of all proteins annotated in the human
proteome [20]. Data was presented as percent of enrichment. The GO terms found to be over/under
represented by a two-tailed Fisher Exact test with a p-value r0.05 were presented, p-values were
R. Sheta et al. / Data in Brief 8 (2016) 342–349348corrected using Bonferroni statistics correction (See Fig. 3 in [1] and Supplementary Table 5). P-values
were additionally transformed to scores (–log10 (p-value)), to determine whether the fold enrichment
is signiﬁcant based on the relative abundance of each GO term in our data sets (pr0.05 is considered
signiﬁcant) (see Fig. 3 and Supplementary Table 5). The GO terms based on the gene list of our study
were compared to the background distribution of annotation based on the genes in the whole gen-
ome that are annotated to the GO Term similar to that applied in [20] (see Fig. 3 and Supplementary
Table 5).Acknowledgments
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